Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Fulvestrant & Breast Cancer / Mammacarcinoma (HR+ Her2-)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Concerning Fulvestrant & Breast Cancer / Mammacarcinoma (HR+) (ER+) (Her2-), Fulvestrant is officially approved by both the FDA and the EMA as a treatment for Breast Cancer / Mammacarcinoma (HR+) (ER+) (Her2-), particularly in advanced or metastatic settings
Boér 2017 Ther Adv Med Oncol 9(7): 465-479
Lee et al. 2017a Cochrane Database Syst Rev 1(1): CD011093
Wang 2020 Transl Cancer Res 9(8): 4464-4468

Fulvestrant was approved by the US FDA in 2002 for treatment of ER-positive metastatic breast cancer (ER + MBC) post-progression on [aromatase inhibitors](brain://V…

References (Sources)

A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy
Xu et al. 2021d
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Turner et al. 2020
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Bidard et al. 2022 J Clin Oncol 40(28): 3246-3256
Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
Jacobson 2022 Oncologist 27(Suppl 1): S7-S8
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner et al. 2018 NEJM 379: 1926-1936
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Loibl et al. 2017
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
Kornblum et al. 2018 JCO 36: 1556–1563

AI Chat

7/1/2026

Chat with our artificial intelligence: